As an infrastructure at the German Center for Infection Research (DZIF), the Clinical Trial Unit tracks DZIF's study activities in the “Healex Site Management System (SMS)”. Studies are sorted by indication and are continuously updated.

The study register has recently been expanded to include the category “COVID-19”. For the first time, not only DZIF study activities are presented here: In order to provide a comprehensive overview in the current pandemic situation of planned and already active COVID-19 studies in Germany, the Clinical Trial Unit is cooperating with researchers from various German Centers for Health Research and other networks.

For researchers: If your study is not yet included in our portal, please contact the project management of the Clinical Trial Unit (angela.steinbach@uk-koeln.de or vassiliki.dimitriou@uk-koeln.de).

RECOVER

AcronymISRCTNEudraCTNCT (clinicaltrials.gov)DRKS
SARS-CoV-2CP-HD-0012020-001632-10

A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease

Status: Planned (Transit Ethics), pub.

Purpose / Objectives

Diagnosis

Trial design

  • Phase II
  • Prospective
  • Randomized
  • Two-arm
  • Cross-over
  • Open Label

Documents (password protected)

Responsibilities in overall trial

Ruprecht-Karls-Universität Heidelberg

National Coordinating Investigator

Prof. Dr. Carsten Müller-Tidow